Glycemic control, blood pressure control and single agent renin-angiotensin-aldosterone system (RAAS) blockade were, until recently, the pillars of managing diabetic kidney disease (DKD). While the introduction of sodium-glucose cotransport-2 (SGLT2) inhibitors has further reduced DKD progression, patients continue to have significant residual risk, underlying the importance of identifying new therapies. In FIDELIO-DKD, Bakris et al. demonstrate that the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone, on top of standard of care, is beneficial in DKD management1.